Shanghai InnoStar Bio-tech Co (688710) Fair Value & Analysis
Healthcare · CN · Market cap 7.4B CNY
Fair value as of: Jul 12, 2026
From 8 valuation models · updated 29 days ago
Share price +41.1% over the past month.
Below-average quality, and screening another 88% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥11.07). The favourable scenario is already priced in.
- Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The models converge in a tight band (¥10.29 to ¥11.07), unusually little disagreement for a valuation.
Price vs Fair Value (23 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
23‑month range ¥22.76 – ¥90.69 · fair‑value band ¥10.29 – ¥11.07 · the ¥90.69 price screens above the ¥10.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Shanghai InnoStar Bio-tech Co (688710) currently trades at ¥90.69, while our model-based Fair Value estimate is ¥10.48, implying the stock looks roughly 88.4% overvalued today. The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Shanghai InnoStar Bio-tech Co generated revenue of 812M CNY at a net margin of -2.9%. Revenue grew 0.4% year over year. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥10.29 (bear case) to ¥11.07 (bull case); at ¥90.69, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 194% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -88%, 688710 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 8 models by family
Widest divergence: Multiples (¥12.05) versus Dividend Discount (¥3.80). Highest evidence: Gordon GGM (70).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 31 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines.
Full company description
Shanghai InnoStar Bio-tech Co., Ltd. provides drug research and development services in China and internationally. The company offers screening and discovery, nonclinical assessment stage, and clinical development stage services in the areas of chemical products, biologics, cell and gene therapeutics, radiopharmaceuticals, and traditional Chinese medicines. The company was founded in 2010 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai InnoStar Bio-tech Co reported revenue of ¥811M in FY2025 versus ¥582M in FY2021, a compound +8.7%/yr. Reported net income was −¥30.5M in FY2025.
688710 screens 88% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Shanghai InnoStar Bio-tech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai InnoStar Bio-tech Co (688710) overvalued or undervalued?
What is the fair value of 688710?
What is the quality score of 688710?
What is the revenue of Shanghai InnoStar Bio-tech Co (688710)?
What is the net profit margin of 688710?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai InnoStar Bio-tech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.